Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 10

PMID 35267430

Authors

Lawrence Kasherman

Shiru Lucy Liu

Katherine Karakasis

Stephanie Lheureux

Affiliations

Soon will be listed here.

Abstract

Since the discovery of angiogenesis and its relevance to the tumorigenesis of gynecologic malignancies, a number of therapeutic agents have been developed over the last decade, some of which have become standard treatments in combination with other therapies. Limited clinical activity has been demonstrated with anti-angiogenic monotherapies, and ongoing trials are focused on combination strategies with cytotoxic agents, immunotherapies and other targeted treatments. This article reviews the science behind angiogenesis within the context of gynecologic cancers, the evidence supporting the targeting of these pathways and future directions in clinical trials.

Citing Articles

Bevacizumab-induced immune thrombocytopenia in an ovarian cancer patient with mixed connective tissue disease: case report and literature review.

Zhang Y, Yang F, Wang J, Fu H, Shen F, Liu J Front Immunol. 2024; 15:1382964.

PMID: 38903494 PMC: 11188369. DOI: 10.3389/fimmu.2024.1382964.

Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms.

Yang S, Fei W, Zhao Y, Wang F, Ye Y, Wang F Int J Nanomedicine. 2023; 18:3035-3046.

PMID: 37312935 PMC: 10259534. DOI: 10.2147/IJN.S411761.

The BAP31/miR-181a-5p/RECK axis promotes angiogenesis in colorectal cancer fibroblast activation.

Zhang Q, Wang C, Li R, Liu J, Wang J, Wang T Front Oncol. 2023; 13:1056903.

PMID: 36895489 PMC: 9989165. DOI: 10.3389/fonc.2023.1056903.

Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma.

Guo X, Sui R, Piao H J Nanobiotechnology. 2022; 20(1):383.

PMID: 35999601 PMC: 9400220. DOI: 10.1186/s12951-022-01584-6.

References

Oza A, Cook A, Pfisterer J, Embleton A, Ledermann J, Pujade-Lauraine E . Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015; 16(8):928-36. PMC: 4648090. DOI: 10.1016/S1470-2045(15)00086-8. View

Moore K, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G . Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021; 39(17):1842-1855. PMC: 8189598. DOI: 10.1200/JCO.21.00306. View

Roland C, Dineen S, Lynn K, Sullivan L, Dellinger M, Sadegh L . Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther. 2009; 8(7):1761-71. DOI: 10.1158/1535-7163.MCT-09-0280. View

Bender D, Sill M, Lankes H, Reyes H, Darus C, Delmore J . A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015; 138(3):507-12. PMC: 4642817. DOI: 10.1016/j.ygyno.2015.07.018. View

Hong D, Kurzrock R, Wheler J, Naing A, Falchook G, Fu S . Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015; 21(21):4801-10. PMC: 4840931. DOI: 10.1158/1078-0432.CCR-14-3063. View

Brown J, Brady W, Schink J, Van Le L, Leitao M, Yamada S . Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2013; 120(3):344-51. PMC: 4250045. DOI: 10.1002/cncr.28421. View

Wang Q, Peng H, Qi X, Wu M, Zhao X . Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther. 2020; 5(1):137. PMC: 7391668. DOI: 10.1038/s41392-020-0199-6. View

Lorusso D, Ferrandina G, Colombo N, Pignata S, Pietragalla A, Sonetto C . Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. Gynecol Oncol. 2019; 155(3):406-412. DOI: 10.1016/j.ygyno.2019.10.013. View

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

10.

Morgan R, Banerjee S, Hall M, Clamp A, Zhou C, Hasan J . Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecol Oncol. 2020; 156(3):545-551. DOI: 10.1016/j.ygyno.2020.01.005. View

11.

Zirlik K, Duyster J . Anti-Angiogenics: Current Situation and Future Perspectives. Oncol Res Treat. 2018; 41(4):166-171. DOI: 10.1159/000488087. View

12.

Vergote I, Bois A, Floquet A, Rau J, Kim J, Del Campo J . Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019; 155(2):186-191. DOI: 10.1016/j.ygyno.2019.08.024. View

13.

Garcia A, Hirte H, Fleming G, Yang D, Tsao-Wei D, Roman L . Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26(1):76-82. DOI: 10.1200/JCO.2007.12.1939. View

14.

Sjoquist K, Espinoza D, Mileshkin L, Ananda S, Shannon C, Yip S . REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecol Oncol. 2021; 161(2):374-381. DOI: 10.1016/j.ygyno.2021.02.002. View

15.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

16.

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Yang J, Liao Y, Mai D, Xie P, Qiang Y, Zheng L . Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis. 2016; 19(2):191-200. DOI: 10.1007/s10456-016-9500-2. View

19.

OReilly T, Lane H, Wood J, Schnell C, Littlewood-Evans A, Brueggen J . Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model. Cancer Chemother Pharmacol. 2010; 67(1):193-200. DOI: 10.1007/s00280-010-1307-z. View

20.

Kuczynski E, Vermeulen P, Pezzella F, Kerbel R, Reynolds A . Vessel co-option in cancer. Nat Rev Clin Oncol. 2019; 16(8):469-493. DOI: 10.1038/s41571-019-0181-9. View